BACKGROUND: Concerns have been raised about the risk of dementia associated with antiestrogen adjuvant therapy in breast cancer, but study results have been inconsistent. We examined whether tamoxifen or other endocrine therapy was associated with dementia risk in a large population of patients with breast cancer. METHODS: We used Danish nationwide medical registries to identify patients with breast cancer diagnosed between 1990 and 2004, use of endocrine therapy, and subsequent diagnoses of dementia. We used Cox regression to estimate the risk of dementia among patients who received five years of tamoxifen or other endocrine therapies. RESULTS: The study included 16,419 patients with breast cancer. In this cohort, 37% were unexposed to endocrine therapy, 9% had five years of tamoxifen therapy, and 54% had other endocrine regimens, some of them containing tamoxifen for less than five years with subsequent aromatase inhibitor therapy. Tamoxifen therapy was associated with a near-null risk of dementia [HR, 1.4; 95% confidence interval (CI), 1.0-1.9], and a null association was observed after death was taken into account as a competing risk (sub-HR, 1.0; 95% CI, 0.76-1.4). CONCLUSIONS: No clinically relevant association between use of tamoxifen or other endocrine therapy and risk of dementia was observed. IMPACT: Our result contradicts earlier research findings suggesting tamoxifen and other endocrine therapies increase the risk of dementia in breast cancer patients.
BACKGROUND: Concerns have been raised about the risk of dementia associated with antiestrogen adjuvant therapy in breast cancer, but study results have been inconsistent. We examined whether tamoxifen or other endocrine therapy was associated with dementia risk in a large population of patients with breast cancer. METHODS: We used Danish nationwide medical registries to identify patients with breast cancer diagnosed between 1990 and 2004, use of endocrine therapy, and subsequent diagnoses of dementia. We used Cox regression to estimate the risk of dementia among patients who received five years of tamoxifen or other endocrine therapies. RESULTS: The study included 16,419 patients with breast cancer. In this cohort, 37% were unexposed to endocrine therapy, 9% had five years of tamoxifen therapy, and 54% had other endocrine regimens, some of them containing tamoxifen for less than five years with subsequent aromatase inhibitor therapy. Tamoxifen therapy was associated with a near-null risk of dementia [HR, 1.4; 95% confidence interval (CI), 1.0-1.9], and a null association was observed after death was taken into account as a competing risk (sub-HR, 1.0; 95% CI, 0.76-1.4). CONCLUSIONS: No clinically relevant association between use of tamoxifen or other endocrine therapy and risk of dementia was observed. IMPACT: Our result contradicts earlier research findings suggesting tamoxifen and other endocrine therapies increase the risk of dementia in breast cancerpatients.
Authors: Jeanne S Mandelblatt; Robert A Stern; Gheorghe Luta; Meghan McGuckin; Jonathan D Clapp; Arti Hurria; Paul B Jacobsen; Leigh Anne Faul; Claudine Isaacs; Neelima Denduluri; Brandon Gavett; Tiffany A Traina; Patricia Johnson; Rebecca A Silliman; R Scott Turner; Darlene Howard; John W Van Meter; Andrew Saykin; Tim Ahles Journal: J Clin Oncol Date: 2014-05-19 Impact factor: 44.544
Authors: Mikayla R Thompson; Jiangong Niu; Xiudong Lei; Malgorzata Nowakowska; Mackenzie R Wehner; Sharon H Giordano; Kevin T Nead Journal: Breast Cancer (Dove Med Press) Date: 2021-04-07
Authors: Steven Jett; Niharika Malviya; Eva Schelbaum; Grace Jang; Eva Jahan; Katherine Clancy; Hollie Hristov; Silky Pahlajani; Kellyann Niotis; Susan Loeb-Zeitlin; Yelena Havryliuk; Richard Isaacson; Roberta Diaz Brinton; Lisa Mosconi Journal: Front Aging Neurosci Date: 2022-03-09 Impact factor: 5.750